Piper Sandler downgraded Point Biopharma (PNT) to Neutral from Overweight with an unchanged price target of $12.50 to reflect the shares trading above Eli Lilly’s (LLY) $12.50 per share acquisition price.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PNT:
- Eli Lilly (NYSE:LLY) Jumps on Analyst Optimism
- Point Biopharma downgraded to Market Perform from Outperform at Leerink
- Point Biopharma downgraded to Market Perform from Outperform at Raymond James
- Point Biopharma downgraded to Hold from Buy at Truist
- Lantheus program validated by Point Biopharma buyout, says Mizuho